Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2016, provides an overview of the Wilms’ Tumor (Nephroblastoma) (Oncology) pipeline landscape.
Wilms’ tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms’ tumor is a rare kidney cancer that primarily affects children.Wilms’ tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Wilms’ Tumor (Nephroblastoma) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms’ Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wilms’ Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms’ Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.
Wilms’ Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms’ Tumor (Nephroblastoma) (Oncology). - The pipeline guide reviews pipeline therapeutics for Wilms’ Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Wilms’ Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Wilms’ Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Wilms’ Tumor (Nephroblastoma) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Wilms’ Tumor (Nephroblastoma) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Wilms’ Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
244 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Kidney Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...
Cancer Pain - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain – Pipeline Review, H1 2020, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape. Cancer pain can be defined as a complex sensation that...
290 pages •
By Asia Market Information & Development Company
• May 2020
China’s demand for Leukemia Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
The Global Oncology Partnering 2014-2020: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
Uterine Cancer Therapeutics & Diagnostics Market Research Report by Cancer Type (Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), by Product (Diagnostics and Therapeutics) - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Uterine Cancer Therapeutics...
The growing prevalence of several types of cancers in cats and dogs, as well as an increase in R&D initiatives regarding cancer management in animals, is contributing to the growth of the market. According to the Veterinary Cancer Society, cancer was the leading cause of death in 47% of dogs, especially those that are over the age of 10, and...
The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. - According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global...